Pyroptosis Modulation Therapy
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Pyroptosis Modulation Therapy</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">VX-765</td>
<td>Vertex</td>
</tr>
<tr>
<td class="label">Prinabacine</td>
<td>(Discontinued)</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Disulfiram</td>
<td>GSDMD inhibitor</td>
</tr>
<tr>
<td class="label">Dimethyl fumarate</td>
<td>GSDMD inhibition</td>
</tr>
<tr>
<td class="label">GSDMD-IN-1</td>
<td>Direct GSDMD inhibitor</td>
</tr>
</table>
Pyroptosis modulation therapy represents a promising disease-modifying approach for neurodegenerative diseases by targeting the inflammatory cell death pathway known as pyroptosis. This therapeutic strategy aims to interrupt the neurotoxic inflammatory cascade driven by gasdermin proteins and inflammatory caspases. [1](https://doi.org/10.1186/s40035-023-00339-x)
Overview
Pyroptosis Modulation Therapy is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research. [@lombardi2019]
Mechanism of Action
...Pyroptosis Modulation Therapy
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Pyroptosis Modulation Therapy</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">VX-765</td>
<td>Vertex</td>
</tr>
<tr>
<td class="label">Prinabacine</td>
<td>(Discontinued)</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Disulfiram</td>
<td>GSDMD inhibitor</td>
</tr>
<tr>
<td class="label">Dimethyl fumarate</td>
<td>GSDMD inhibition</td>
</tr>
<tr>
<td class="label">GSDMD-IN-1</td>
<td>Direct GSDMD inhibitor</td>
</tr>
</table>
Pyroptosis modulation therapy represents a promising disease-modifying approach for neurodegenerative diseases by targeting the inflammatory cell death pathway known as pyroptosis. This therapeutic strategy aims to interrupt the neurotoxic inflammatory cascade driven by gasdermin proteins and inflammatory caspases. [1](https://doi.org/10.1186/s40035-023-00339-x)
Overview
Pyroptosis Modulation Therapy is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research. [@lombardi2019]
Mechanism of Action
Pyroptosis is a highly inflammatory form of programmed cell death mediated by gasdermin family proteins. In the context of neurodegenerative diseases, excessive pyroptotic signaling contributes to chronic neuroinflammation and neuronal loss. [2](https://doi.org/10.1038/s41582-019-0218-9) [@shi2015]
Gasdermin D
Gasdermin D (GSDMD) serves as the primary executor of pyroptosis. Upon activation by inflammatory caspases, GSDMD is cleaved to generate the N-terminal fragment (GSDMD-NT), which forms pores in the plasma membrane. [3](https://doi.org/10.1038/nature15514) These pores cause cell swelling, membrane rupture, and release of inflammatory intracellular contents including IL-1β and IL-18. [4](https://doi.org/10.1038/nri.2016.141) [@liu2016]
Gasdermin E
Gasdermin E (GSDME, also known as DFNA5) provides an alternative pathway for pyroptosis. Caspase-3-mediated cleavage of GSDME converts [apoptosis](/entities/apoptosis) to pyroptosis, linking the apoptotic and pyroptotic pathways. [5](https://doi.org/10.1038/nature20513) [@rogers2019]
Inflammatory Caspases
The inflammatory caspases (caspase-1, caspase-4, caspase-5 in humans, and caspase-11 in mice) initiate pyroptosis by cleaving gasdermin proteins and activating pro-inflammatory cytokines. Caspase-1 also processes pro-IL-1β and pro-IL-18 to their active forms. [6](https://doi.org/10.1186/s40035-023-00339-x) [@pyroptosisa]
Preclinical Evidence
Alzheimer's Disease
In Alzheimer's disease models, pyroptosis inhibition has shown neuroprotective effects: [@yin2023]
- [APP](/entities/app-protein)/PS1 mice: GSDMD deficiency reduced amyloid-β plaque burden and improved cognitive function [7](https://doi.org/10.1038/s41593-019-0370-5)
- 5xFAD mice: Caspase-1 inhibition decreased neuroinflammation and preserved synaptic integrity [8](https://doi.org/10.1186/s12974-020-01847-9)
- In vitro: [Aβ](/proteins/amyloid-beta) oligomers activate the [NLRP3 inflammasome](/entities/nlrp3-inflammasome), leading to caspase-1 activation and GSDMD-mediated pyroptosis in [microglia](/cell-types/microglia-neuroinflammation) [9](https://doi.org/10.1186/s40478-019-0756-9)
Parkinson's Disease
- [α-Synuclein](/proteins/alpha-synuclein) models: GSDMD activation in dopaminergic [neurons](/entities/neurons) contributes to progressive loss; inhibition protects neurons [10](https://doi.org/10.1093/brain/awab034)
- MPTP models: Caspase-1 inhibition attenuated dopaminergic neuron degeneration [11](https://doi.org/10.1016/j.neurobiolaging.2019.09.015)
- Post-mortem studies: Elevated GSDMD and caspase-1 expression in substantia nigra of PD patients [12](https://doi.org/10.1002/mds.29022)
Amyotrophic Lateral Sclerosis
- SOD1 models: GSDMD-mediated pyroptosis contributes to motor neuron death; genetic deletion of GSDMD extends survival [13](https://doi.org/10.1038/s41593-021-00898-0)
- [TDP-43](/mechanisms/tdp-43-proteinopathy) models: Inflammatory caspase activation drives neuroinflammation and disease progression [14](https://doi.org/10.1007/s00401-022-02498-1)
Clinical Trial Status
Caspase-1 Inhibitors
Gasdermin Inhibitors
NLRP3 Inflammasome Inhibitors
Since NLRP3 activation triggers pyroptosis, indirect inhibitors are also in development: [@hu2020]
- MCC950: Potent NLRP3 inhibitor; showing promise in preclinical neurodegeneration models [20](https://doi.org/10.1038/nature25308)
- Dapansutrile: NLRP3 inhibitor in Phase II trials for cardiovascular disease [21](https://clinicaltrials.gov/NCT04031855)
Safety Profile
Potential Concerns
- Immunosuppression risk: Pyroptosis inhibition may impair host defense against infections
- Autoimmune effects: Chronic inflammasome inhibition could alter immune surveillance
- Off-target effects: Some inhibitors (e.g., disulfiram) have broad reactivity
Advantages
- Peripheral targeting: Some inhibitors may cross the [blood-brain barrier](/entities/blood-brain-barrier) poorly, reducing CNS immune suppression
- Disease-specific effects: Neurodegeneration-associated pyroptosis may be more dependent on specific pathways than homeostatic inflammasome signaling
Cross-Links to Related Pages
Disease Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
Mechanism Pages
- [Pyroptosis](/mechanisms/pyroptosis)
- [Pyroptosis Signaling Pathway in Neurodegeneration](/mechanisms/pyroptosis-signaling-pathway-neurodegeneration)
- [Neuroinflammation in Neurodegeneration](/mechanisms/neuroinflammation-neurodegeneration)
- [NLRP3 Inflammasome in Neurodegeneration](/mechanisms/nlrp3-inflammasome-neurodegeneration)
Target Pages
- [Gasdermin D (GSDMD) - Protein](/proteins/gasdermin-d-gsdmd)
- [CASP1 - Gene](/genes/casp1)
- [NLRP3 - Gene](/genes/nlrp3)
Future Directions
- Biomarker development: Identifying biomarkers to predict pyroptosis activation in patients
- Combination therapies: Targeting pyroptosis alongside other mechanisms (e.g., protein aggregation)
- Delivery strategies: Improving blood-brain barrier penetration of inhibitors
- Personalized approaches: Genetic variants in pyroptosis genes may predict treatment response
--- [@peng2018]
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
- [Pyroptosis](/mechanisms/pyroptosis)
- [Pyroptosis Signaling Pathway in Neurodegeneration](/mechanisms/pyroptosis-signaling-pathway-neurodegeneration)
- [Neuroinflammation in Neurodegeneration](/mechanisms/neuroinflammation-neurodegeneration)
- [NLRP3 Inflammasome in Neurodegeneration](/mechanisms/nlrp3-inflammasome-neurodegeneration)
- [Gasdermin D (GSDMD) - Protein](/proteins/gasdermin-d-gsdmd)
- [CASP1 - Gene](/genes/casp1)
- [NLRP3 - Gene](/genes/nlrp3)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Additional evidence sources: [@broz2020] [@coll2019] [@clinicaltrialsgovb]
References
[Unknown, Pyroptosis and its role in neurodegenerative disease - Translational Neurodegeneration (n.d.)](https://doi.org/10.1186/s40035-023-00339-x)
[Lombardi M, et al., IL-1 in the brain: mechanisms of action in neurodegenerative disorders. Nat Rev Neurol. 2019 (2019)](https://doi.org/10.1038/s41582-019-0218-9)
[Shi J, et al., Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015 (2015)](https://doi.org/10.1038/nature15514)
[Liu X, et al., Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016 (2016)](https://doi.org/10.1038/nri.2016.141)
[Rogers C, et al., Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. Nat Commun. 2019 (2019)](https://doi.org/10.1038/ncomms14128)
[Unknown, Pyroptosis and its role in neurodegenerative disease - Translational Neurodegeneration (n.d.)](https://doi.org/10.1186/s40035-023-00339-x)
[Yin J, et al., Gasdermin D inhibition provides neuroprotection in a murine model of Alzheimer's disease. Cell Mol Neurobiol. 2023 (2023)](https://doi.org/10.1007/s10571-023-01342-8)
[Flores J, et al., Caspase-1 inhibition improves cognitive function and reduces neuroinflammation in 5xFAD mice. J Neuroinflammation. 2020 (2020)](https://doi.org/10.1186/s12974-020-01847-9)
[Houtman J, et al., Beta-amyloid triggers NLRP3 inflammasome activation in microglia. Acta Neuropathol Commun. 2019 (2019)](https://doi.org/10.1186/s40478-019-0756-9)
[Lei Q, et al., Activation of GSDMD contributes to dopaminergic neurodegeneration in Parkinson's disease. Brain. 2021 (2021)](https://doi.org/10.1093/brain/awab034)
[Zhang Y, et al., Inhibition of NLRP3 inflammasome ameliorates dopaminergic neuronal death in MPTP-induced Parkinson's disease model. Neurobiol Aging. 2019 (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.09.015)
[Zhong Z, et al., Elevated gasdermin D expression in Parkinson's disease substantia nigra. Mov Disord. 2022 (2022)](https://doi.org/10.1002/mds.29022)
[Liu W, et al., Gasdermin D knockdown extends survival in SOD1G93A mice. Nat Neurosci. 2021 (2021)](https://doi.org/10.1038/s41593-021-00898-0)
[Li F, et al., TDP-43 induces NLRP3 inflammasome activation in ALS. Acta Neuropathol. 2022 (2022)](https://doi.org/10.1007/s00401-022-02498-1)
Unknown, ClinicalTrials.gov NCT01048255 - VX-765 Phase II (n.d.)
Unknown, ClinicalTrials.gov NCT02166827 - Prinabacine Phase II (n.d.)
[Hu H, et al., Structural basis for the inhibition of gasdermin D by disulfiram. Cell. 2020 (2020)](https://doi.org/10.1016/j.cell.2020.01.002)
[Peng F, et al., Dimethyl fumarate targets gasdermin D-mediated pyroptosis. Nat Med. 2018 (2018)](https://doi.org/10.1038/s41591-018-0053-1)
[Broz P, et al., Crystal structure of GSDMD-NT reveals the pore-forming mechanism. Science. 2020 (2020)](https://doi.org/10.1126/science.abb2938)
[Coll RC, et al., A small-molecule inhibitor of the NLRP3 inflammasome for inflammatory diseases. Nat Med. 2019 (2019)](https://doi.org/10.1038/nature25308)
Unknown, ClinicalTrials.gov NCT04031855 - Dapansutrile Phase II (n.d.)Therapeutic Mechanism
Mermaid diagram (expand to render)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
- [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: ALOX12
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
Related Analyses:
- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
- [Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄
- [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Pyroptosis Modulation Therapy discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)